Company intelligence
Citeline
End-to-end clinical, regulatory & competitive intelligence helping pharma, biotech & CROs navigate trials and compliance
About Citeline
At Citeline (a Norstella company), we are a global leader in clinical trial intelligence, data, and insights for the life sciences and pharmaceutical industries. We help organizations accelerate drug development, enhance transparency, and improve clinical outcomes through real‑time, decision‑ready intelligence across the entire drug lifecycle. Our solutions provide one of the most comprehensive and continuously updated views of global clinical trials, investigators, sites, pipelines, regulatory requirements, and competitive landscapes—enhanced with AI, curated datasets, and expert analysis. This empowers pharma, biotech, and CRO partners to plan smarter, recruit faster, maintain compliance, and reduce development risk. Our core offerings include: • Clinical Trial Intelligence: Real‑time global data on trials, investigators, and sites. • Drug Development Intelligence: Pipeline insights, market assessments & competitive analysis. • Regulatory & Compliance Intelligence: Tools to support disclosure compliance, mitigate risk & streamline submission workflows. • Competitive Intelligence: Industry and therapeutic‑area insights to stay ahead of evolving markets. Powered by machine learning, real‑world data, and expert‑led research, Citeline delivers reliable, actionable intelligence used by global pharmaceutical companies, CROs, and life sciences innovators. As part of Norstella, we work together to accelerate the connection of treatments to patients around the world.
Verified activity
Signals from Citeline
16 published signals
Presence & Recognition
Citeline is exhibiting at Nordic Life Science Days at Booth C:04
Reported by Citeline
Products & Services
Citeline produced a film for BBC StoryWorks Commercial Productions as part of the Rewriting Cancer series featuring Madeline Naylor, the Chief Clinician, who turned personal loss into professional purpose.
Reported by Citeline
Presence & Recognition
Citeline is attending the Outsourcing in Clinical Trials Event Series #SoCal next week.
Reported by Daniel Hoopes
Legal & Regulatory
Citeline learned that the European Medicines Agency is preparing to pilot a new agile scientific advice pathway in Q1 2027.
Reported by Victor Reis
Presence & Recognition
Citeline is live in Stockholm at Nordic Life Science Days
Reported by Annabel Griffiths
Presence & Recognition
Citeline released a new episode of the Small Biotechs Big Decisions podcast featuring Claire Riches and Carrie Melvin discussing clinical trial execution.
Reported by Citeline
Research & Knowledge
Citeline provided feasibility data and insights to help Biorasi complete a Phase III oncology trial with 89% site validation, 8 priority countries, and a 15–20% predicted enrollment lift from a protocol optimization.
Reported by Citeline
Research & Knowledge
Citeline published the Annual Completed Clinical Trials Report 2026, which highlights stronger outcomes even with fewer trials.
Reported by Citeline
Presence & Recognition
Citeline hosted a Pharma Friday event featuring answers to last week's Guess that Pharma questions
Reported by Citeline
Capital & Finance
Citeline moved its lead program into the clinic through the Function ALS study in June 2026.
Reported by Victor Reis
Customers & Market
Citeline reported that RedHill switched tracks with Ferring in-License and Apotex out-Licensing deals in September 2026.
Reported by Joseph Haas
Research & Knowledge
Citeline reported that previously treated patients receiving Rasonque achieved a median overall survival of 13.2 months in the Phase III RASolute 302 trial compared to 6.7 months with chemotherapy.
Reported by Victor Reis
Research & Knowledge
Citeline noted that Revolution Medicines is studying daraxonrasib across several additional settings including first-line metastatic pancreatic cancer, adjuvant pancreatic cancer, RAS G12D-mutated pancreatic cancer, and KRAS-mutated non-small cell lung cancer.
Reported by Victor Reis
Legal & Regulatory
Citeline reported that the FDA approved Rasonque (daraxonrasib) from Revolution Medicines for metastatic pancreatic ductal adenocarcinoma on 26 August 2026.
Reported by Victor Reis
Capital & Finance
Citeline reported that the company entered commercialization from a strong financial position with approximately $3.9bn in cash reported at the end of June and an extensive late-stage development programme underway.
Reported by Victor Reis
Products & Services
Citeline built on the right side of the pharma AI divide by developing eval frameworks, provenance tracking, and FDAAA compliance tooling.
Reported by Utsav Sharma